Oculis Announces Expert Katie Kazem as Chief Legal Officer
Oculis has appointed Katie Kazem as Chief Legal Officer to lead legal, compliance, and corporate governance as the company...
Oculis has appointed Katie Kazem as Chief Legal Officer to lead legal, compliance, and corporate governance as the company...
Agios has its first broad rare-hematology launch in hand. Following FDA approval in December, Aqvesme (mitapivat 100 mg) is...
Agios Pharmaceuticals will report fourth quarter and full-year 2025 results on February 12, 2026, via webcast. For a rare-hematology...
Beyond Air reported fiscal Q3 revenue of $2.2 million, up 105% year over year and 21% sequentially, turned a...
Medicenna has updated mid‑stage data for its beta‑selective IL‑2 superkine, MDNA11, reporting objective response rates of 36% as monotherapy...
Rezolute reported a mixed clinical and corporate update: its Phase 3 SUNRIZE trial in congenital hyperinsulinism did not meet...
Beyond Air reported fiscal Q3 results with revenue up 105% year over year to $2.2 million, maintained full-year guidance...
CRISPR Therapeutics reported fourth-quarter and full-year 2025 results, spotlighting commercial traction for CASGEVY and a pipeline tilting from ex...
PacBio reported fourth-quarter 2025 revenue of $44.6 million, up 14% year over year and 16% sequentially, bringing full-year revenue...
Grace Therapeutics has a PDUFA date of April 23, 2026 for GTX-104, its intravenous formulation of nimodipine for aneurysmal...